Opdivo fails to hit key target in small cell lung cancer study
Bristol-Myers Squibb’s immunotherapy Opdivo did not hit the primary target of a late-stage study testing its efficacy in certain patients with small cell lung cancer.
Read More
Tag: amrubicin
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
